Chemical Information | |
Antiviral agent ID | DrugRepV_0888 | |
Antiviral agent name | Ceftibuten | |
IUPAC Name | (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | |
SMILES (canonical) | C1C=C(N2C(S1)C(C2=O)NC(=O)C(=CCC(=O)O)C3=CSC(=N3)N)C(=O)O | |
SMILES (isomeric) | C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=C\CC(=O)O)/C3=CSC(=N3)N)C(=O)O | |
Molecular Formula | C15H14N4O6S2 | |
Molecular Weight (g/mol) | 410.42 | |
InChl | InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1 | |
Common Name | Ceftibuten | |
Synonyms | (+)-(6R,7R)-7-((Z)-2-(2-amino-4-Thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid | Ceftibutene | Ceftibuteno | Ceftibutenum | cis-Ceftibuten | |
Structural Information | |
|
|
Clinical Information | |
Category | Antiinfectives For Systemic Use
| |
Primary Indication (Clinical trial phases) | Approved
| |
Biological Information | |
Primary Indication (Disease Category) | Infectious Disease
| |
Primary Indication (Disease) | Bacterial infections
| |
Secondary Indication | Zika virus (ZIKV) NA MEX_I_7 | |
Secondary Indication (Approaches) | Experimental-HTS | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Huh-7
| |
Secondary Indication (Mode of viral infection) | Adsorption
| |
Secondary Indication (Viral titer) | 0.4 MOI
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Time of drug delivery) | Pre infection (1 hour)
| |
Secondary Indication (Duration of drug delivery) | 24-26 hours
| |
Secondary Indication (Drug concentration) | 13.8 μM
| |
Secondary Indication (Cell based assay) | Fluorescence-based assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | Percentage Inhibition [ 53.895 % ] | |
Reference | Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Muñoz.A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection..Cell Host Microbe. 2016 Aug 10;20(2):259-70. doi: 10.1016/j.chom.2016.07.004. Epub 2016 Jul 28. PMID:27476412
| |
Comment | Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.
| |